Investigational Device Exemption (IDE) for the development of Adagloxad Simolenin (OBI-822) was approved by the US Food and Drug Administration (FDA) for its use in OBI-822 Phase III Clinical Trial

Date of occurrence of the event: Jul 27, 2018 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office Reciprocal shareholding ratios: N/A Cause of occurrence: OBI received a letter from the US Food and Drug Administration（FDA）on July 26 (US time) that the Investigational Device Exemption (IDE) for […]